Anti-allergic Psidium guajava extracts exert an antitumor effect by inhibition of T regulatory cells and resultant augmentation of Th1 cells

Anticancer Research

Volumn 25, Issue 6 A, 2005, Pages 3763-3770

  Seo, Naohiro ^a   Ito, Taisuke ^a   Wang, Naili ^b   Yao, Xinsheng ^b   Tokura, Yoshiki ^c   Furukawa, Fukumi ^d   Takigawa, Masahiro ^a   Kitanaka, Susumu ^e  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e NIHON UNIVERSITY   (Japan)

Author keywords

Herbal medicine; Psidium guajava; T regulatory cell; Th1 Th2 balance; Tumor vaccine

Indexed keywords

ANTIALLERGIC AGENT; CD4 ANTIGEN; INTERLEUKIN 10; PLANT EXTRACT; PSIDIUM GUAJAVA EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BIDENS; BIDENS PARVIFLORA; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CELL ASSAY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; FEMALE; GUAVA; HERBAL MEDICINE; INOCULATION; LYMPHOCYTE COUNT; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

ANIMALS; BIDENS; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; PSIDIUM; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 27844455985     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Girolomoni G, Sebastiani S, Albanesi C and Cavani A: T-cell subpopulations in the development of atopic and contact allergy. Curr Opin Immunol 13: 733-737, 2001.
2. Moffatt MF and Cookson WO: Genetics of asthma and inflammation: the status. Curr Opin Immunol 11: 606-609, 1999.
3. Lanchbury JS and Pitzalis C: Cellular immune mechanisms in rheumatoid arthritis and other inflammatory arthritides. Curr Opin Immunol 5: 918-924, 1993.
4. Shigeyama M, Ohgaya O, Takeuchi H, Hino T and Kawashima Y: Formulation design of ointment base suitable for healing of lesions in treatment of bedsores. Chem Pharm Bull 49: 129-133, 2001.
5. Takatsu K: Interleukin-5. Curr Opin Immunol 4: 299-306, 1992.
6. Stuehr DJ and Marietta MA: Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 82: 7738-7742, 1985.
7. We XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP et al: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 575: 408-411, 1995.
8. Dorsch W, Bittinger M, Kaas A, Muller A, Kreher B and Wagner H: Antiasthmatic effects of Galphimia glauca, gallic acid, and related compounds prevent allergen- and platelet-activating factor-induced bronchial obstruction as well as bronchial hyperreactivity in guinea pigs. Int Arch Allergy Immunol 97: 1-7, 1992.
9. Kane CJ, Menna JH, Sung CC and Yeh YC: Methylgallate, methyl-3,4,5-trihydoxybenzoate, is a potent and highly specific inhibitor of herpes simplex virus in vitro. II. Antiviral activity of methyl gallate and its derivatives. Biosci Rep 8: 95-102, 1988.
10. Wang N, Yao X, Ishii R and Kitanaka S: Antiallergic agents from natural sources. 3. Structures and inhibitory effects on nitric oxide production and histamine release of five novel polyacetylene glucosides from Bidens parviflora WILLD. Chem Pharm Bull 49: 938-942, 2001.
11. Ishii R, Horie M, Saito K, Arisawa M and Kitanaka S: Inhibitory effects of phloroglucinol derivatives from Mallotus japonicus on nitric oxide production by a murine macrophage-like cell line, RAW 264.7, activated by lipopolysaccharide and interferon-γ. Biochim Biophys Acta 1568: 74-82, 2001.
12. Kato K, Yamashita S, Kitanaka S and Toyoshima S: Effect of gallic acid derivatives on secretion of Th1 cytokines and Th2 cytokines from anti CD3-stimulated spleen cells. Yakugaku Zasshi 121: 451-457, 2001.
13. Schwartz M and Cohen IR: Autoimmunity can benefit self-maintenance. Immunol Today 21: 265-268, 2000.
14. Hori S, Takahashi T and Sakaguchi S: Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 81: 331-371, 2003.
15. Seo N, Hayakawa S, Takigawa M and Tokura Y: Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4+ T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103: 449-457, 2001.
16. Takahashi T and Sakaguchi S: Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med 3: 693-706, 2003.
17. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC et al: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196: 1335-1346, 2002.
18. Seo N, Hayakawa S and Tokura Y: Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 12: 291-300, 2002.
19. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742, 1997.
20. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo C et al: CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 198: 259-266, 2003.
21. Cosmi L, Liotta F, Angeli R, Mazzinghi B, Santarlasci V, Manetti R et al: Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 103: 3117-3121, 2004.
22. Bellinghausen I, Klostermann B, Knop J and Saloga J: Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol 111: 862-868, 2003.
23. Umetsu DT, Akbari O and Dekruyff RH: Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 112: 480-487, 2003.
24. Sekimoto M, Tsuji T, Matsuzaki J, Chamoto K, Koda T, Nemoto K et al: Functional expression of the TrkC gene, encoding a high affinity receptor for NT-3, in antigen-specific T helper type 2 (Th2) cells. Immunol Lett 88: 221-226, 2003.
25. Iwamoto N, Xano HJ, Yoshioka T, Shiraga H, Nitta K, Muraki T et al: Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci 66: 221-226, 2000.
26. Gnan SO and Demello MT: Inhibition of Staphyhcoccus aureus by aqueous Goiaba extracts. J Ethnopharm 68: 103-108, 1999.
27. Becker Y: The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers: a review and hypothesis. Virus Genes 28: 5-18, 2004.
28. Iwasaki M, Saito K, Takemura M, Sekikawa K, Fujii H, Yamada Y et al: TNF-α contributes to the development of allergic rhinitis in mice. J Allergy Clin Immunol 772: 134-140, 2003.
29. Durham SR: The inflammatory nature of allergic disease. Clin Exp Allergy 6: 20-24, 1998.
30. Salomon B and Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19: 225-252, 2001.
31. Snowden N and Kay RA: Immunology of systemic rheumatoid disease. Br Med Bull 51: 437-448, 1995.
32. Tokura Y, Seo N, Yagi H, Furukawa F and Takigawa M: Cross-reactivity in murine fluoroquinolone photoallergy: exclusive usage of TCR Vβ13 by immune T cells that recognize fluoroquinolone-photomodified cells. J Immunol 160: 3719-3728, 1998.
33. Viola JP and Rao A: Molecular regulation of cytokine gene expression during the immune response. J Clin Immunol 19: 98-108, 1999.
34. Adorini L, Gregori S, Magram J and Trembleau S: The role of IL-12 in the pathogenesis of Th1 cell-mediated autoimmune diseases. Ann NY Acad Sci 795: 208-215, 1996.
35. Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, Ohlen C et al: Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection. Immunity 20: 293-303, 2004.
36. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J et al: CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 185: 720-727, 2002.
37. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G et al: Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 75: 5550-5558, 2001.
38. Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA and MacDonald KS: Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-γ and interleukin-10 responses. J Infect Dis 184: 1268-1278, 2001.
39. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM and Nixon DF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 2454-2459, 2004.
40. Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336, 2003.
41. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y et al: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118, 2004.
42. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A et al: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251, 2004.
43. Phan GO, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003.